Hugh M. Davis - 02 Dec 2024 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACRS	Employee Stock Option (Right to Buy)	Award	$0	+375,000		$0.000000	375,000	02 Dec 2024	Common Stock	375,000	$3.96	Direct	F1, F2
transaction	ACRS	Restricted Stock Units	Award	$0	+107,000		$0.000000	107,000	02 Dec 2024	Common Stock	107,000		Direct	F1, F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The securities were granted pursuant to the Issuer's 2024 Inducement Plan (the "Plan") as a material inducement to the Reporting Person's acceptance of employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4).
F2	Exercisable with respect to 25% of the shares subject to the option vesting on each of the first, second, third and fourth anniversaries of December 2, 2024 (in each case rounded down to the nearest whole share, except for the last vesting installment), subject to recipient's Continuous Service (as defined in the Plan) through each such date.
F3	Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
F4	Four year vesting with 25% of the shares subject to the restricted stock units vesting on each of the first, second, third and fourth anniversaries of December 2, 2024 (in each case rounded down to the nearest whole share, except for the last vesting installment), subject to recipient's Continuous Service through each such date.